Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis

Dattoli Cancer Center and Brachytherapy Research Institute

Status: Completed

Conditions: Prostate Cancer Patients Undergoing External Radiation and Seed Implantation

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00264017

L0087

Details and patient eligibility

About

In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely. This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects.

Sex: Male

Ages: 45 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males age 45-80 years
• Diagnosis of prostate cancer
• Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation
• Baseline AUA score< or =12
• May be on antiandrogenand/or alpha reductase therapy
• Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the primary therapy for prostate cancer with curatives intent -

Exclusion criteria

• History of insulin-dependent diabetes
• Uncontrolled hypertention
• History of symptomtic hypotension (including syncope and dizziness)
• Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary Retention
• Pre-existing prostatitis either continuous or intermittent
• Concurrent use of any other anticholinergics
• previous or concurrent usage of LHRH agonist